Edesa Biotech grants 136,000 stock options to CEO, CFO, and President at $3.71

Edesa Biotech, Inc.

Pardeep Nijhawan (CEO) granted 49,000 options; monthly vesting over 36 months, 10-year term.
Kathi Niffenegger (CFO) granted 43,500 options; Michael Brooks (President) also granted 43,500 options.
Exercise price set at $3.71 per share, equal to closing price on grant date (Feb 28, 2022).
Options vest monthly over 36 months; no immediate change in executive compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.